Merck CEO, FDA Are Called to Testify on Vioxx
Merck & Co. Chief Executive Raymond Gilmartin and Food and Drug Administration officials have been called to testify before Congress on Nov. 18 over safety problems with the company’s withdrawn arthritis drug Vioxx, said Iowa Republican Sen. Charles E. Grassley, chairman of the Senate Finance Committee.
In separate congressional action, House Government Reform Committee Chairman Thomas M. Davis (R-Va.) said he wrote Merck seeking all documents related to a FDA panel’s review of the drug, various communications between the company and the FDA, and other documents.
Get the L.A. Times Politics newsletter
Deeply reported insights into legislation, politics and policy from Sacramento, Washington and beyond. In your inbox three times per week.
You may occasionally receive promotional content from the Los Angeles Times.
